MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2017 International Congress

    Which factors predict patient satisfaction with botulinum toxin treatment for cervical dystonia?

    C. Colosimo, V. Misra, D. Charles, T.M. Chung, S. Om, P. Maisonobe (Terni, Italy)

    Objective: Investigate which factors influence patient satisfaction with botulinum neurotoxin type A (BoNT-A) treatment for cervical dystonia (CD) in routine practice. Background: We have previously…
  • 2017 International Congress

    Clinical and demographics of cervical dystonia related to the direction of the neck movement

    K. Asanuma (Kyoto, Japan)

    Objective: The objectives of this report is to survey whether the type of torticollis (i.e. rotation, retrocolis and anterocolis) is related to the clinical characteristics…
  • 2017 International Congress

    Clinical effects are persistent at the end of one abobotulinumtoxinA injection cycle in cervical dystonia – results from a meta-analysis of 1091 subjects

    R. Trosch, V. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

    Objective: Evaluate the impact of one injection cycle of abobotulinumtoxinA (AboBoNT-A; Dysport®) on the clinical characteristics of cervical dystonia (CD). Background: The pharmacologic effects of…
  • 2017 International Congress

    Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study

    K. Dashtipour, Z. Mari, J. Jankovic, C. Adler, M. Schwartz, M. Brin (Loma Linda, CA, USA)

    Objective: To explore minimal clinically important change perceived by patients as beneficial by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) using data from the…
  • 2017 International Congress

    Oromandibular dystonia (OMD): A Prospective, Single-Blind Trial of AbobotulinumtoxinA (AboA)

    S. Factor, M. Silver, J. Hanfelt, E. Sperine, L. Scorr, A. Freeman, H. Jinnah (Atlanta, GA, USA)

    Objective: To examine the safety and efficacy of AboA in OMD Background: OMD causes involuntary movements of the lower facial, masticatory, and lingual muscles.  The…
  • 2017 International Congress

    Dystonia treatment in an international cohort: a longitudinal analysis

    S. Pirio Richardson, A. Wegele, A. Deligtisch, F. Qeadan (Albuquerque, NM, USA)

    Objective: To assess the change in therapy for dystonia over time Background: Although botulinum toxin (BoNT) injections are the gold standard therapy for patients with focal…
  • 2017 International Congress

    Clinical profile of patients with blepharospasm

    S. Kaleagasi, O. Dogu (Mersin, Turkey)

    Objective: To present the clinical profile of 61 patients with blepharospasm who were treated with onabotulinum toxin injections.  Background: Blepharospasm is a focal dystonia that…
  • 2017 International Congress

    Clinical analysis of patients with servical dystonia who Botulinum toxin injection is performed: 10 years experience of Ege University Neurology Department of Movement Disorders Clinic

    A. Acarer, S. Ciftci, Z. Colakoglu (Izmir, Turkey)

    Objective: In this study, it is aimed to analysis of clinical features and  treatment efficiency  in patients with servical dystonia who are performed Botulinum injection…
  • 2017 International Congress

    Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

    R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

    Objective: To identify the epidemiological profile of patients treated with botulinum toxin type A (BTA) in a tertiary clinic in Brazil. Background: BTA is used to…
  • 2017 International Congress

    Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity

    D. Dressler, F. Adib Saberi (Hamburg, Germany)

    Objective: To study whether incobotulinumtoxinA (INCO), a new, low-antigenicity botulinum toxin (BT) drug, increases BT antibody (BTAB) titers in patients with antibody-induced therapy failure (ABTF)…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley